Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

α‐Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML

ChemMedChem(2024)10.1002/cmdc.202400622Source: DataRank Database

α‐Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML is a research paper published in ChemMedChem (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.74)OA: hybridTopics (56)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Lorenza Destro ORCID,Luca Mologni ORCID,Valentina Crippa ORCID,Paolo Zardi ORCID,Francesco Fini ORCID

Live enrichment

PubMed:39331039 PMC:PMC11694611 OpenAlex:https://openalex.org/W4402920278

NIAID NIH HHS

Grant: R01 AI072219

AIRC

Grant: 24828

National Institutes of Health

Grant: 5R01AI072219-12

Understanding B-Lactam Resistance in Acinetobacter baumannii

National Institute of Allergy

FWCI

0.74

Citation Percentile

0.7%

Citation Trend

2024

2025

hybridLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cmdc.202400622

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cmdc.202400622

publisherhttps://chemistry-europe.onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.202400622

journalhttps://doi.org/10.1002/cmdc.202400622

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39331039

Fields of Study

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsHistone Deacetylase Inhibitors Research0301 basic medicine0303 health sciences03 medical and health sciencesfms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteBoronic AcidsProtein Kinase InhibitorsTriazolesAntineoplastic AgentsStructure-Activity RelationshipMolecular StructureCell Line, TumorDose-Response Relationship, DrugDrug Screening Assays, AntitumorCell Proliferation

MeSH Terms

Antineoplastic AgentsBoronic AcidsDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansStructure-Activity RelationshipTriazolesMolecular StructureLeukemia, Myeloid, AcuteCell Line, TumorProtein Kinase InhibitorsCell Proliferationfms-Like Tyrosine Kinase 3

Keywords

ScaffoldChemistryCancer researchMedicineBiomedical engineeringAcute myeloid leukemiaBoron ChemicalFlt3 Protein KinaseMolecular StructureDose-Response Relationship, DrugAntineoplastic AgentsTriazolesBoronic AcidsLeukemia, Myeloid, AcuteStructure-Activity RelationshipAcute Myeloid Leukemia; FLT3 Protein Kinase; Boronic Acidsfms-Like Tyrosine Kinase 3Cell Line, TumorHumansAcute Myeloid Leukemia; Boron Chemical; FLT3 Protein Kinase;Drug Screening Assays, AntitumorProtein Kinase InhibitorsResearch ArticleCell Proliferation

Sustainable Development Goals

SDG 0: Good health and well-being